NFE2L2 and cancer: These subtypes are characterized by differential expression of hepatic stem/progenitor markers (LIN28B, SALL4, AFP), hepatobiliary markers (HNF, NOTCH1), metabolic factors (NFE2L2), and cancer-related pathways (P53, TERT).